Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L2ZY
|
||||
| Former ID |
DNCL002239
|
||||
| Drug Name |
X-82
|
||||
| Indication | Advanced solid tumor; Macular degeneration [ICD9: 140-199, 362.5; ICD10:C00-C75, C7A, C7B, H35.3] | Phase 1 | [1] | ||
| Company |
Tyrogenex West Palm Beach
|
||||
| Target and Pathway | |||||
| Target(s) | Platelet-derived growth factor receptor | Target Info | Modulator | [2] | |
| Vascular endothelial growth factor receptor 1 | Target Info | Modulator | [2] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| HIF-1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| Pathway Interaction Database | Glypican 1 network | ||||
| HIF-2-alpha transcription factor network | |||||
| S1P3 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| VEGFR1 specific signals | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Reactome | Neurophilin interactions with VEGF and VEGFR | ||||
| VEGF binds to VEGFR leading to receptor dimerization | |||||
| WikiPathways | Focal Adhesion | ||||
| Signaling by VEGF | |||||
| Angiogenesis | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of Tyrogenex. | ||||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 695817). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.